By inducing immediate tumor reduction, expanding effector and memory CD4 + and CD8+ T cell populations, and enhancing interferon-gamma and granzyme B activity, it primes the immune system to eliminate residual micrometastatic disease and reduces the risk of recurrence (39, 51, 104). This evidence concerns the gene GZMB and neoplasm.